Bright Minds Biosciences (NASDAQ:DRUG) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Bright Minds Biosciences (NASDAQ:DRUG) from a sell rating to a hold rating in a research note released on Saturday morning.

A number of other brokerages have also issued reports on DRUG. BTIG Research reaffirmed a “buy” rating and set a $147.00 target price on shares of Bright Minds Biosciences in a research report on Monday, August 17th. Zacks Research raised Bright Minds Biosciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Oppenheimer lowered Bright Minds Biosciences to a “market perform” rating in a research note on Thursday. Benchmark restated a “buy” rating on shares of Bright Minds Biosciences in a report on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $220.00 target price (up from $190.00) on shares of Bright Minds Biosciences in a research report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Bright Minds Biosciences presently has an average rating of “Buy” and a consensus target price of $143.83.

Bright Minds Biosciences Price Performance

Bright Minds Biosciences stock opened at $77.42 on Friday. Bright Minds Biosciences has a 12-month low of $38.00 and a 12-month high of $123.75. The company has a market capitalization of $753.30 million, a price-to-earnings ratio of -37.22 and a beta of -5.27. The firm’s fifty day moving average price is $72.44 and its 200 day moving average price is $77.11.

Bright Minds Biosciences (NASDAQ:DRUG) last issued its quarterly earnings data on Monday, August 17th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $1.05. Analysts forecast that Bright Minds Biosciences will post -2.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bright Minds Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vivo Capital LLC lifted its position in shares of Bright Minds Biosciences by 99.4% during the third quarter. Vivo Capital LLC now owns 501,617 shares of the company’s stock worth $30,428,000 after purchasing an additional 250,045 shares during the last quarter. MPM Bioimpact LLC acquired a new position in Bright Minds Biosciences in the fourth quarter worth about $17,961,000. Balyasny Asset Management L.P. bought a new stake in Bright Minds Biosciences in the third quarter valued at about $11,339,000. Millennium Management LLC increased its holdings in Bright Minds Biosciences by 376.9% in the first quarter. Millennium Management LLC now owns 192,557 shares of the company’s stock valued at $6,946,000 after buying an additional 152,178 shares during the last quarter. Finally, Ikarian Capital LLC raised its stake in Bright Minds Biosciences by 933.1% during the fourth quarter. Ikarian Capital LLC now owns 159,421 shares of the company’s stock valued at $12,441,000 after buying an additional 143,990 shares in the last quarter. Institutional investors own 40.52% of the company’s stock.

Bright Minds Biosciences News Roundup

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for fiscal 2026 and each quarter of fiscal 2027. The firm now projects a fiscal 2026 loss of $3.15 per share, compared with its prior estimate of a $5.92 loss, and a fiscal 2027 loss of $5.83 per share versus a previous $9.07 loss. These revisions indicate expectations for slower losses and improving financial performance.
• Positive Sentiment: The analyst also improved its fiscal 2028 and fiscal 2029 forecasts, narrowing projected losses to $5.04 and $2.79 per share, respectively, from $7.93 and $4.04. The model continues to forecast a return to profitability in fiscal 2030, with projected EPS of $2.41.
• Neutral Sentiment: Despite the improved outlook, Bright Minds remains unprofitable, with a current-year consensus estimate of a $3.85-per-share loss. The company’s valuation therefore remains highly dependent on the progress and commercial potential of its drug-development pipeline.
• Negative Sentiment: HC Wainwright reduced its fiscal 2030 EPS estimate to $2.41 from $3.09, signaling some moderation in its long-term profitability assumptions. However, the firm retained its Buy rating and $145 target.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.